Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Role of epigenetic mechanisms in cisplatin-induced toxicity

Full text
Author(s):
Franca Quintanilha, Julia Coelho [1] ; Francinette Saavedra, Kathleen [2] ; Visacri, Marilia Berlofa [3] ; Moriel, Patricia [1, 4] ; Salazar, Luis A. [2]
Total Authors: 5
Affiliation:
[1] Univ Estadual Campinas, Sch Med Sci, Campinas, SP - Brazil
[2] Univ La Frontera, Ctr Mol Biol & Pharmacogenet, Sci & Technol Bioresource Nucleus, 01145 Francisco Salazar St, Temuco 4811230 - Chile
[3] Fundacao Ctr Med Campinas, Campinas, SP - Brazil
[4] Univ Estadual Campinas, Fac Pharmaceut Sci, 200 Candido Portinari St, BR-13083871 Campinas, SP - Brazil
Total Affiliations: 4
Document type: Review article
Source: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY; v. 137, p. 131-142, MAY 2019.
Web of Science Citations: 1
Abstract

Cisplatin (CDDP) is a highly effective antineoplastic agent, widely used in the treatment of various malignant tumors. However, its major problems are side effects associated to toxicity. Considerable inter-individual differences have been reported for CDDP-induced toxicity due to genetic and epigenetic factors. Genetic causes are well described; however, epigenetic modifications are not fully addressed. In the last few years, many evidences were found linking microRNA to the development of CDDP-mediated toxicity, particularly nephrotoxicity. In this review, we described how genetic and epigenetic modifications can be important determinants for the development of toxicity in patients treated with CDDP, and how these alterations may be interesting biomarkers for monitoring toxicity induced by CDDP. Considering the validation in different studies, we suggest that miR-34a, -146b, -378a, -192, and -193 represent an attractive study group to evaluate potential biomarkers to detect CDDP-related nephrotoxicity. (AU)

FAPESP's process: 17/11329-4 - Evaluation of microRNAs, oxidized biomolecules and polymorphisms in the CYP2E1, ABCB1 and ABCC2 genes as possible biomarkers of cisplatin-induced toxicities in head and neck cancer patients
Grantee:Patricia Moriel
Support Opportunities: Regular Research Grants
FAPESP's process: 17/02338-0 - MicroRNAs and oxidated molecules as possible biomarkers of cisplatin-induced nephrotoxicity in patients with head and neck cancer
Grantee:Júlia Coelho França Quintanilha
Support Opportunities: Scholarships in Brazil - Doctorate